Our results further extend the possibility that GLP-1R agonist also alleviates non-diabetes-related oxidative stress and endothelial dysfunction, and elucidate the role of LOX-1 in mediating this process, suggesting that GLP-1R agonist may be used to reduce non-diabetes-related atherosclerotic events in the future. Here, OLR1 is linked to endothelial dysfunction.